Federal Register / Vol. 77, No. 129 / Thursday, July 5, 2012 / Notices 39737 

San Rafael, California; Canadian Solar 

Inc. of Kitchener, Ontario, Canada; and 

Canadian Solar (USA) Inc. of San 

Ramon, California. Id. 

On May 25, 2012, all of the private 

parties filed a joint motion to terminate 

the investigation based on confidential 

settlement agreements under 

Commission rules 210.21(a)(2) and (b). 

The Commission investigative attorney 

supported the motion. 

On June 13, 2012, the presiding ALJ 

issued an ID (Order No. 11) granting the 

joint motion. No party petitioned for 

review of the ID. 

The authority for the Commission’s 

determination is contained in section 

337 of the Tariff Act of 1930, as 

amended, 19 U.S.C. 1337, and in section 

210.42(h) of the Commission’s Rules of 

Practice and Procedure, 19 CFR 

210.42(h). 

By order of the Commission. 

Issued: June 29, 2012. 

Lisa R. Barton, 

Acting Secretary to the Commission. 

[FR Doc. 2012–16433 Filed 7–3–12; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Notice of Lodging of Proposed 

Consent Decree With Dairyland Power 

Cooperative Under the Clean Air Act 

Pursuant to 28 CFR 50.7, notice is 

hereby given that on June 28, 2012, a 

proposed Consent Decree in United 

States of America v. Dairyland Power 

Cooperative (‘‘Dairyland’’), Civil Action 

No. 12-cv-462, was lodged with the 

United States District Court for the 

Western District of Wisconsin. 

In this civil enforcement action under 

the federal Clean Air Act (‘‘Act’’), the 

United States alleges that Dairyland—an 

electric utility—failed to comply with 

certain requirements of the Act intended 

to protect air quality. The complaint 

alleges that Dairyland violated the 

Prevention of Significant Deterioration 

(‘‘PSD’’) and Title V provisions of the 

Act, 42 U.S.C. 7401–7671 et seq., and 

related state and federal implementing 

regulations, at the Alma/J.P. Madgett 

Generating Station, a coal-fired power 

plant in Buffalo County, Wisconsin, and 

the Genoa Generating Station, a coalfired power plant in Vernon County, 

Wisconsin. The alleged violations arise 

from the construction of modifications 

at the power plants and operation of the 

plants in violation of PSD and Title V 

requirements. The complaint alleges 

that Dairyland failed to obtain 

appropriate permits and failed to install 

and apply required pollution control 

devices to reduce emissions of various 

air pollutants. The complaint seeks both 

injunctive relief and civil penalties. 

The proposed Decree lodged with the 

Court requires installation and 

operation of certain pollution control 

devices at the Alma/J.P. Madgett and 

Genoa plants, and the permanent 

cessation of operations of certain units 

at the Alma/J.P. Madgett plant. The 

settlement will reduce emissions of 

sulfur dioxide (‘‘SO2’’), nitrogen oxides 

(‘‘NOX’’), and particular matter (‘‘PM’’) 

through emission control requirements 

and limitations specified by the 

proposed Decree. Dairyland will also 

fund environmental projects at a cost of 

at least $5 million to mitigate the 

alleged adverse effects of its past 

violations, and will pay a civil penalty 

of $950,000. 

The Department of Justice will receive 

for a period of thirty (30) days from the 

date of this publication comments 

relating to the Consent Decree. 

Comments should be addressed to the 

Assistant Attorney General, 

Environment and Natural Resources 

Division, and either emailed to 

pubcomment-ees.enrd@usdoj.gov or 

mailed to P.O. Box 7611, U.S. 

Department of Justice, Washington, DC 

20044–7611, and should refer to United 

States v. Dairyland Power Cooperative, 

D.J. Ref. 90–5–2–1–10163. 

During the public comment period, 

the Consent Decree may also be 

examined on the following Department 

of Justice Web site, http:// 

www.usdoj.gov/enrd/ 

Consent_Decrees.html. A copy of the 

Consent Decree may also be obtained by 

mail from the Consent Decree Library, 

P.O. Box 7611, U.S. Department of 

Justice, Washington, DC 20044–7611 or 

by faxing or emailing a request to 

‘‘Consent Decree Copy’’ 

(EESCDCopy.ENRD@usdoj.gov), fax no. 

(202) 514–0097, phone confirmation 

number (202) 514–5271. If requesting a 

copy from the Consent Decree Library 

by mail, please enclose a check in the 

amount of $24.25 (25 cents per page 

reproduction cost) payable to the U.S. 

Treasury or, if requesting by email or 

fax, forward a check in that amount to 

the Consent Decree Library at the 

address given above. 

Maureen Katz, 

Assistant Chief, Environmental Enforcement 

Section, Environment and Natural Resources 

Division. 

[FR Doc. 2012–16353 Filed 7–3–12; 8:45 am] 

BILLING CODE 4410–15–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–363] 

Controlled Substances: Proposed 

Adjustment to the Aggregate 

Production Quotas for 2012 

AGENCY: Drug Enforcement 

Administration (DEA), Department of 

Justice. 

ACTION: Notice with request for 

comments. 

SUMMARY: This notice proposes to adjust 

the 2012 aggregate production quotas for 

several controlled substances in 

schedules I and II of the Controlled 

Substances Act (CSA). 

DATES: Electronic comments must be 

submitted and written comments must 

be postmarked on or before August 6, 

2012. Commenters should be aware that 

the electronic Federal Docket 

Management System will not accept 

comments after midnight Eastern Time 

on the last day of the comment period. 

ADDRESSES: To ensure proper handling 

of comments, please reference ‘‘Docket 

No. DEA–363’’ on all electronic and 

written correspondence. DEA 

encourages all comments be submitted 

electronically through http:// 

www.regulations.gov using the 

electronic comment form provided on 

that site. An electronic copy of this 

document is also available at the 

http://www.regulations.gov Web site for 

easy reference. Paper comments that 

duplicate the electronic submission are 

not necessary as all comments 

submitted to www.regulations.gov will 

be posted for public review and are part 

of the official docket record. Should 

you, however, wish to submit written 

comments via regular or express mail, 

they should be sent to the Drug 

Enforcement Administration, Attention: 

DEA Federal Register Representative/ 

ODL, 8701 Morrissette Drive, 

Springfield, VA 22152. 

FOR FURTHER INFORMATION CONTACT: John 

W. Partridge, Chief, Liaison and Policy 

Section, Drug Enforcement 

Administration, 8701 Morrissette Drive, 

Springfield, VA 22152, Telephone: (202) 

307–4654. 

SUPPLEMENTARY INFORMATION: 

Posting of Public Comments 

Please note that all comments 

received are considered part of the 

public record and made available for 

public inspection online at http:// 

www.regulations.gov and in the DEA’s 

public docket. Such information 

includes personal identifying 


TKELLEY on DSK3SPTVN1PROD with NOTICES
39738 Federal Register / Vol. 77, No. 129 / Thursday, July 5, 2012 / Notices 

information (such as your name, 

address, etc.) voluntarily submitted by 

the commenter. 

If you want to submit personal 

identifying information (such as your 

name, address, etc.) as part of your 

comment, but do not want it to be 

posted online or made available in the 

public docket, you must include the 

phrase ‘‘PERSONAL IDENTIFYING 

INFORMATION’’ in the first paragraph 

of your comment. You must also place 

all the personal identifying information 

you do not want posted online or made 

available in the public docket in the first 

paragraph of your comment and identify 

what information you want redacted. 

If you want to submit confidential 

business information as part of your 

comment, but do not want it to be 

posted online or made available in the 

public docket, you must include the 

phrase ‘‘CONFIDENTIAL BUSINESS 

INFORMATION’’ in the first paragraph 

of your comment. You must also 

prominently identify confidential 

business information to be redacted 

within the comment. If a comment has 

so much confidential business 

information that it cannot be effectively 

redacted, all or part of that comment 

may not be posted online or made 

available in the public docket. 

Personal identifying information and 

confidential business information 

identified and located as set forth above 

will be redacted, and the comment, in 

redacted form, will be posted online and 

placed in the DEA’s public docket file. 

Please note that the Freedom of 

Information Act applies to all comments 

received. If you wish to inspect the 

agency’s public docket file in person by 

appointment, please see the FOR

FURTHER INFORMATION CONTACT

paragraph. 

Background 

Section 306 of the CSA (21 U.S.C. 

826) requires that the Attorney General 

establish aggregate production quotas 

for each basic class of controlled 

substance listed in schedules I and II. 

This responsibility has been delegated 

to the Administrator of the DEA by 28 

CFR 0.100. The Administrator, in turn, 

has redelegated this function to the 

Deputy Administrator, pursuant to 28 

CFR 0.104. The 2012 established 

aggregate production quotas for 

controlled substances in schedules I and 

II were published in the Federal 

Register (76 FR 78044) on December 15, 

2011. That notice stipulated that, as 

provided for in 21 CFR 1303.13, all 

aggregate production quotas are subject 

to adjustment. 

Analysis for Proposed Revised 2012 

Aggregate Production Quotas 

DEA now proposes to adjust the 

established 2012 aggregate production 

quotas for some schedule I and II 

controlled substances. In proposing the 

adjustment, DEA has taken into account 

the criteria that DEA is required to 

consider in accordance with 21 CFR 

1303.13. DEA proposes the adjustment 

of the aggregate production quotas for 

basic classes of schedule I and II 

controlled substances by considering (1) 

Changes in demand for the class, 

changes in the national rate of net 

disposal for the class, and changes in 

the rate of net disposal by the registrants 

holding individual manufacturing 

quotas for the class; (2) whether any 

increased demand or changes in the 

national and/or individual rates of net 

disposal are temporary, short term, or 

long term; (3) whether any increased 

demand can be met through existing 

inventories, increased individual 

manufacturing quotas, or increased 

importation without increasing the 

aggregate production quota; (4) whether 

any decreased demand will result in 

excessive inventory accumulation by all 

persons registered to handle the class; 

and (5) other factors affecting the 

medical, scientific, research, and 

industrial needs of the United States 

and lawful export requirements, as the 

Administrator finds relevant. 

In determining whether to propose 

adjustments to the 2012 aggregate 

production quotas, DEA considered 

updated information obtained from 

2011 year-end inventories, 2011 

disposition data submitted by quota 

applicants, estimates of the medical 

needs of the United States, product 

development, and other information 

made available to DEA after the initial 

aggregate production quotas had been 

established. The Deputy Administrator, 

therefore, proposes to adjust the 2012 

aggregate production quotas for some 

schedule I and II controlled substances, 

expressed in grams of anhydrous acid or 

base, as follows: 

Basic class 

Previously 

established 

2012 quotas 

Proposed 

adjusted 2012 

quotas 

Schedule I 

1-[1-(2-Thienyl)cyclohexyl]piperidine ................................................................................................................. 0 g .................... 5 g. 

1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200) ............................................................................. 45 g .................. No Change. 

1-Butyl-3-(1-naphthoyl)indole (JWH-073) .......................................................................................................... 45 g .................. No Change. 

1-Methyl-4-phenyl-4-propionoxypiperidine ......................................................................................................... 2 g .................... No Change. 

1-Pentyl-3-(1-naphthoyl)indole (JWH-018) ........................................................................................................ 45 g .................. No Change. 

2,5-Dimethoxyamphetamine .............................................................................................................................. 2 g .................... 12 g. 

2,5-Dimethoxy-4-ethylamphetamine (DOET) .................................................................................................... 2 g .................... 12 g. 

2,5-Dimethoxy-4-n-propylthiophenethylamine ................................................................................................... 2 g .................... 12 g. 

3-Methylfentanyl ................................................................................................................................................. 2 g .................... No Change. 

3-Methylthiofentanyl ........................................................................................................................................... 2 g .................... No Change. 

3,4-Methylenedioxyamphetamine (MDA) .......................................................................................................... 22 g .................. 30 g. 

3,4-Methylenedioxy-N-methylcathinone (methylone) ........................................................................................ 8 g .................... 12 g. 

3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ........................................................................................... 15 g .................. 24 g. 

3,4-Methylenedioxymethamphetamine (MDMA) ............................................................................................... 22 g .................. 30 g. 

3,4-Methylenedioxypyrovalerone (MDPV) ......................................................................................................... 8 g .................... 12 g. 

3,4,5-Trimethoxyamphetamine .......................................................................................................................... 2 g .................... 12 g. 

4-Bromo-2,5-dimethoxyamphetamine (DOB) .................................................................................................... 2 g .................... 12 g. 

4-Bromo-2,5-dimethoxyphenethylamine (2-CB) ................................................................................................ 2 g .................... 12 g. 

4-Methoxyamphetamine .................................................................................................................................... 77 g .................. 88 g. 

4-Methylaminorex .............................................................................................................................................. 2 g .................... 12 g. 

4-Methyl-2,5-dimethoxyamphetamine (DOM) .................................................................................................... 2 g .................... 12 g. 

4-Methyl-N-methylcathinone (mephedrone) ...................................................................................................... 8 g .................... 12 g. 

5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol ....................................................................... 68 g .................. No Change. 

5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol ......................................................................... 53 g .................. No Change. 


TKELLEY on DSK3SPTVN1PROD with NOTICES
Federal Register / Vol. 77, No. 129 / Thursday, July 5, 2012 / Notices 39739 

Basic class 

Previously 

established 

2012 quotas 

Proposed 

adjusted 2012 

quotas 

5-Methoxy-3,4-methylenedioxyamphetamine .................................................................................................... 2 g .................... 12 g. 

5-Methoxy-N,N-diisopropyltryptamine ................................................................................................................ 2 g .................... 12 g. 

Acetyl-alpha-methylfentanyl ............................................................................................................................... 2 g .................... No Change. 

Acetyldihydrocodeine ......................................................................................................................................... 2 g .................... No Change. 

Acetylmethadol .................................................................................................................................................. 2 g .................... No Change. 

Allylprodine ........................................................................................................................................................ 2 g .................... No Change. 

Alphacetylmethadol ............................................................................................................................................ 2 g .................... No Change. 

Alpha-ethyltryptamine ........................................................................................................................................ 2 g .................... 12 g. 

Alphameprodine ................................................................................................................................................. 2 g .................... No Change. 

Alphamethadol ................................................................................................................................................... 2 g .................... No Change. 

Alpha-methylfentanyl ......................................................................................................................................... 2 g .................... No Change. 

Alpha-methylthiofentanyl .................................................................................................................................... 2 g .................... No Change. 

Alpha-methyltryptamine (AMT) .......................................................................................................................... 2 g .................... 12 g. 

Aminorex ............................................................................................................................................................ 2 g .................... 12 g. 

Benzylmorphine ................................................................................................................................................. 2 g .................... No Change. 

Betacetylmethadol ............................................................................................................................................. 2 g .................... No Change. 

Beta-hydroxy-3-methylfentanyl .......................................................................................................................... 2 g .................... No Change. 

Beta-hydroxyfentanyl ......................................................................................................................................... 2 g .................... No Change. 

Betameprodine ................................................................................................................................................... 2 g .................... No Change. 

Betamethadol ..................................................................................................................................................... 2 g .................... No Change. 

Betaprodine ........................................................................................................................................................ 2 g .................... No Change. 

Bufotenine .......................................................................................................................................................... 3 g .................... No Change. 

Cathinone ........................................................................................................................................................... 4 g .................... 12 g. 

Codeine-N-oxide ................................................................................................................................................ 602 g ................ No Change. 

Diethyltryptamine ............................................................................................................................................... 2 g .................... 12 g. 

Difenoxin ............................................................................................................................................................ 50 g .................. No Change. 

Dihydromorphine ................................................................................................................................................ 3,608,000 g ...... No Change. 

Dimethyltryptamine ............................................................................................................................................ 7 g .................... 18 g. 

Gamma-hydroxybutyric acid .............................................................................................................................. 47,000,000 g .... No Change. 

Heroin ................................................................................................................................................................ 20 g .................. No Change. 

Hydromorphinol .................................................................................................................................................. 54 g .................. No Change. 

Hydroxypethidine ............................................................................................................................................... 2 g .................... No Change. 

Ibogaine ............................................................................................................................................................. 5 g .................... No Change. 

Lysergic acid diethylamide (LSD) ...................................................................................................................... 16 g .................. No Change. 

Marihuana .......................................................................................................................................................... 21,000 g ........... No Change. 

Mescaline ........................................................................................................................................................... 5 g .................... 13 g. 

Methaqualone .................................................................................................................................................... 10 g .................. No Change. 

Methcathinone ................................................................................................................................................... 4 g .................... 12 g. 

Methyldihydromorphine ...................................................................................................................................... 2 g .................... No Change. 

Morphine-N-oxide .............................................................................................................................................. 655 g ................ No Change. 

N-Benzylpiperazine ............................................................................................................................................ 2 g .................... 12 g. 

N,N-Dimethylamphetamine ................................................................................................................................ 2 g .................... 12 g. 

N-Ethylamphetamine ......................................................................................................................................... 2 g .................... 12 g. 

N-Hydroxy-3,4-methylenedioxyamphetamine .................................................................................................... 2 g .................... 12 g. 

Noracymethadol ................................................................................................................................................. 2 g .................... No Change. 

Norlevorphanol ................................................................................................................................................... 52 g .................. No Change. 

Normethadone ................................................................................................................................................... 2 g .................... No Change. 

Normorphine ...................................................................................................................................................... 18 g .................. No Change. 

Para-fluorofentanyl ............................................................................................................................................. 2 g .................... No Change. 

Phenomorphan .................................................................................................................................................. 2 g .................... No Change. 

Pholcodine ......................................................................................................................................................... 2 g .................... No Change. 

Properidine ......................................................................................................................................................... 2 g .................... No Change. 

Psilocybin ........................................................................................................................................................... 2 g .................... No Change. 

Psilocyn .............................................................................................................................................................. 2 g .................... No Change. 

Tetrahydrocannabinols ...................................................................................................................................... 393,000 g ......... No Change. 

Thiofentanyl ....................................................................................................................................................... 2 g .................... No Change. 

Tilidine ................................................................................................................................................................ 10 g .................. No Change. 

Trimeperidine ..................................................................................................................................................... 2 g .................... No Change. 

Schedule II 

1-Phenylcyclohexylamine .................................................................................................................................. 2 g .................... No Change. 

1-Piperdinocyclohexanecarbonitrile ................................................................................................................... 2 g .................... 27 g. 

4-Anilino-N-phenethyl-4-piperidine (ANPP) ....................................................................................................... 1,800,000 g ...... No Change. 

Alfentanil ............................................................................................................................................................ 15,000 g ........... 19,550 g. 

Alphaprodine ...................................................................................................................................................... 2 g .................... No Change. 

Amobarbital ........................................................................................................................................................ 40,007 g ........... No Change. 

Amphetamine (for conversion) .......................................................................................................................... 8,500,000 g.

Amphetamine (for sale) * ................................................................................................................................... 25,300,000 g .... 33,400,000 g. 


TKELLEY on DSK3SPTVN1PROD with NOTICES
39740 Federal Register / Vol. 77, No. 129 / Thursday, July 5, 2012 / Notices 

Basic class 

Previously 

established 

2012 quotas 

Proposed 

adjusted 2012 

quotas 

* DEA has determined that the revised total quantity to provide for the estimated medical, scientific, research, and industrial needs of the United 

States, lawful export requirements, and the establishment and maintenance of reserve stock is 29,400,000 g. DEA has further determined 

that an additional 4,000,000 g is necessary to provide for future research and development needs and unexpected emergencies that could 

affect market availability. 

Carfentanil .......................................................................................................................................................... 0 g .................... 5 g. 

Cocaine .............................................................................................................................................................. 216,000 g ......... No Change. 

Codeine (for conversion) ................................................................................................................................... 65,000,000 g .... No Change. 

Codeine (for sale) .............................................................................................................................................. 39,605,000 g .... No Change. 

Dextropropoxyphene .......................................................................................................................................... 7 g .................... No Change. 

Dihydrocodeine .................................................................................................................................................. 400,000 g ......... No Change. 

Diphenoxylate .................................................................................................................................................... 900,000 g ......... No Change. 

Ecgonine ............................................................................................................................................................ 83,000 g ........... No Change. 

Ethylmorphine .................................................................................................................................................... 2 g .................... No Change. 

Fentanyl ............................................................................................................................................................. 1,428,000 g ...... No Change. 

Glutethimide ....................................................................................................................................................... 2 g .................... No Change. 

Hydrocodone (for sale) ...................................................................................................................................... 59,000,000 g .... 63,000,000 g. 

Hydromorphone ................................................................................................................................................. 3,455,000 g ...... 3,628,000 g. 

Isomethadone .................................................................................................................................................... 4 g .................... No Change. 

Levo-alphacetylmethadol (LAAM) ...................................................................................................................... 3 g .................... No Change. 

Levomethorphan ................................................................................................................................................ 5 g .................... No Change. 

Levorphanol ....................................................................................................................................................... 3,600 g ............. No Change. 

Lisdexamfetamine .............................................................................................................................................. 12,000,000 g .... No Change. 

Meperidine ......................................................................................................................................................... 5,500,000 g ...... No Change. 

Meperidine Intermediate-A ................................................................................................................................ 5 g .................... No Change. 

Meperidine Intermediate-B ................................................................................................................................ 9 g .................... No Change. 

Meperidine Intermediate-C ................................................................................................................................ 5 g .................... No Change. 

Metazocine ......................................................................................................................................................... 5 g .................... No Change. 

Methadone (for sale) ......................................................................................................................................... 20,000,000 g .... No Change. 

Methadone Intermediate .................................................................................................................................... 26,000,000 g .... No Change. 

Methamphetamine ............................................................................................................................................. 3,130,000 g ...... No Change. 

[750,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 2,331,000 grams for methamphetamine mostly for 

conversion to a schedule III product; and 49,000 grams for methamphetamine (for sale)] 

Methylphenidate ................................................................................................................................................. 56,000,000 g .... No Change. 

Morphine (for conversion) .................................................................................................................................. 83,000,000 g .... No Change. 

Morphine (for sale) ............................................................................................................................................ 39,000,000 g .... No Change. 

Nabilone ............................................................................................................................................................. 20,502 g ........... No Change. 

Noroxymorphone (for conversion) ..................................................................................................................... 7,200,000 g ...... No Change. 

Noroxymorphone (for sale) ................................................................................................................................ 401,000 g ......... 1,981,000 g. 

Opium (powder) ................................................................................................................................................. 63,000 g ........... 73,000 g. 

Opium (tincture) ................................................................................................................................................. 1,000,000 g ...... No Change. 

Oripavine ............................................................................................................................................................ 9,800,000 g ...... 15,300,000 g. 

Oxycodone (for conversion) .............................................................................................................................. 5,600,000 g ...... No Change. 

Oxycodone (for sale) ......................................................................................................................................... 98,000,000 g .... 98,700,000 g. 

Oxymorphone (for conversion) .......................................................................................................................... 12,800,000 g .... No Change. 

Oxymorphone (for sale) ..................................................................................................................................... 5,500,000 g ...... No Change. 

Pentobarbital ...................................................................................................................................................... 34,000,000 g .... No Change. 

Phenazocine ...................................................................................................................................................... 5 g .................... No Change. 

Phencyclidine ..................................................................................................................................................... 24 g .................. No Change. 

Phenmetrazine ................................................................................................................................................... 2 g .................... No Change. 

Phenylacetone ................................................................................................................................................... 16,000,000 g .... No Change. 

Racemethorphan ............................................................................................................................................... 2 g .................... No Change. 

Remifentanil ....................................................................................................................................................... 2,500 g ............. No Change. 

Secobarbital ....................................................................................................................................................... 336,002 g ......... No Change. 

Sufentanil ........................................................................................................................................................... 5,000 g ............. No Change. 

Tapentadol ......................................................................................................................................................... 5,400,000 g ...... No Change. 

Thebaine ............................................................................................................................................................ 116,000,000 g .. No Change. 

Aggregate production quotas for all 

other schedule I and II controlled 

substances included in 21 CFR 1308.11 

and 1308.12 remain at zero. Pursuant to 

21 CFR part 1303, the Deputy 

Administrator may adjust the 2012 

aggregate production quotas and 

individual manufacturing quotas 

allocated for the year. 

Comments 

Pursuant to 21 CFR 1303.11 and 

1303.13, any interested person may 

submit written comments on or 

objections to these proposed 

determinations. Based on comments 

received in response to this Notice, the 

Deputy Administrator may hold a 

public hearing on one or more issues 

raised. In the event the Deputy 

Administrator decides in his sole 

discretion to hold such a hearing, the 

Deputy Administrator will publish a 

notice of any such hearing in the 

Federal Register. After consideration of 

any comments and after a hearing, if one 

is held, the Deputy Administrator will 

publish in the Federal Register a Final 


TKELLEY on DSK3SPTVN1PROD with NOTICES
Federal Register / Vol. 77, No. 129 / Thursday, July 5, 2012 / Notices 39741 

Order determining any adjustment of 

the aggregate production quota. 

Dated: June 28, 2012. 

Michele M. Leonhart, 

Administrator. 

[FR Doc. 2012–16396 Filed 7–3–12; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Application; Myoderm 

Pursuant to Title 21 Code of Federal 

Regulations 1301.34(a), this is notice 

that on May 9, 2012, Myoderm, 48 East 

Main Street, Norristown, Pennsylvania 

19401, made application to the Drug 

Enforcement Administration (DEA) for 

registration as an importer of the 

following basic classes of controlled 

substances: 

Drug Schedule 

Amphetamine (1100) .................... II 

Lisdexamfetamine (1205) ............. II 

Methylphenidate (1724) ................ II 

Pentobarbital (2270) ..................... II 

Nabilone (7379) ............................ II 

Codeine (9050) ............................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Hydrocodone (9193) ..................... II 

Levomethorphan (9210) ............... II 

Meperidine (9230) ........................ II 

Methadone (9250) ........................ II 

Methadone intermediate (9254) ... II 

Morphine (9300) ........................... II 

Oxymorphone (9652) ................... II 

Fentanyl (9801) ............................ II 

The company plans to import the 

listed controlled substances in finished 

dosage form for clinical trials, and 

research. 

The import of the above listed basic 

classes of controlled substances would 

be granted only for analytical testing 

and clinical trials. This authorization 

does not extend to the import of a 

finished FDA approved or nonapproved dosage form for commercial 

distribution in the United States. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic classes of controlled 

substances listed in schedule I or II, 

which fall under the authority of section 

1002(a)(2)(B) of the Act 21 U.S.C. 

952(a)(2)(B) may, in the circumstances 

set forth in 21 U.S.C. 958(i), file 

comments or objections to the issuance 

of the proposed registration and may, at 

the same time, file a written request for 

a hearing on such application pursuant 

to 21 CFR 1301.43, and in such form as 

prescribed by 21 CFR 1316.47. 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than August 6, 2012. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 

21 CFR 1301.34(b), (c), (d), (e), and (f). 

As noted in a previous notice published 

in the Federal Register on September 

23, 1975, 40 FR 43745–46, all applicants 

for registration to import a basic class of 

any controlled substance in schedules I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: June 28, 2012. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2012–16493 Filed 7–3–12; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

National Institute of Corrections 

Solicitation for a Cooperative 

Agreement—Curricula Review and 

Revision: NIC Trainer Development 

Series 

AGENCY: National Institute of 

Corrections, U.S. Department of Justice. 

ACTION: Solicitation for a Cooperative 

Agreement. 

SUMMARY: The National Institute of 

Corrections’ (NIC) Academy Division is 

soliciting proposals from organizations, 

groups, or individuals to enter into a 

cooperative agreement for the review, 

revision, and/or development of 

competency-based, blended modality 

training curricula with the aim of 

providing corrections agencies and 

professionals with the knowledge, 

skills, and abilities needed to train and 

develop their staff. 

DATES: Application must be received by 

4 p.m. (EDT) on Friday, July 20, 2012. 

ADDRESSES: Mailed applications must be 

sent to: Director, National Institute of 

Corrections, 320 First Street NW., Room 

5002, Washington, DC 20534. 

Applicants are encouraged to use 

Federal Express, UPS, or similar service 

to ensure delivery by the due date. 

Hand delivered applications should 

be brought to 500 First Street NW., 

Washington, DC 20534. At the front 

desk, dial 7–3106, extension 0 for 

pickup. 

Faxed applications will not be 

accepted. Electronic applications can be 

submitted via http://www.grants.gov. 

FOR FURTHER INFORMATION CONTACT: All 

technical or programmatic questions 

concerning this announcement should 

be directed to Michael Guevara, 

Correctional Program Specialist, 

National Institute of Corrections. Mr. 

Guevara can be reached by calling 800– 

995–6429, ext. 6617, or by email at 

mguevar@bop.gov. In addition to the 

direct reply, all questions and responses 

will be posted on NIC’s Web site at 

www.nicic.gov for public review (the 

names of those submitting questions 

will not be posted). The Web site will 

be updated regularly and postings will 

remain on the Web site until the closing 

date of this cooperative agreement 

solicitation. Only questions received by 

12 p.m. (EDT) on July 13, 2012 will be 

posted on the NIC Web site. 

SUPPLEMENTARY INFORMATION: 

Overview: NIC is revitalizing its 

trainer development series with the goal 

of helping corrections agencies and 

trainers improve staff training and 

development. NIC is interested in 

updating some of its curricula, 

including ‘‘Training Design and 

Development,’’ ‘‘Foundation Skills for 

Trainers,’’ ‘‘Building Agency Success: 

Developing an Effective FTO/OJT 

Training Program,’’ and ‘‘Training for 

Training Directors.’’ NIC is also 

interested in the development of a 

model Training for Trainers template 

that could be applied broadly, enabling 

agencies to train trainers in existing 

curricula. 

All curricula will follow the 

Instructional Theory into Practice (ITIP) 

model and will incorporate blended 

learning strategies. A copy of the ‘‘ITIP 

Toolkit,’’ which may be useful in 

helping awardees develop acceptable 

curricula, is available on the NIC Web 

site at http://nicic.gov/Library/024773. 

An essential component of this project 

will be the incorporation of current 

research on adult learning and 

performance. The use of multiple 

delivery technologies is required. 

Background: NIC has prioritized 

capacity building in corrections 

agencies for decades. While NIC 

frequently relied on traditional 

classroom-based training in the past, the 

emergence of new technologies and the 


TKELLEY on DSK3SPTVN1PROD with NOTICES